Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc announces approval of suglat tablets in Japan


Friday, 17 Jan 2014 12:30am EST 

Astellas Pharma Inc:Says obtained the marketing approval of selective SGLT2 inhibitor Suglat 25mg and 50mg tablets for the treatment of type 2 diabetes in Japan.Says the company filed an application for approval in Mar. 2013. 

Company Quote

1809.0
-1.0 -0.06%
28 Jan 2015